Published: May 10, 2025
Language: Английский
Cell, Journal Year: 2022, Volume and Issue: 185(15), P. 2789 - 2805
Published: July 1, 2022
Language: Английский
Citations
149
Pharmacological Research, Journal Year: 2024, Volume and Issue: 201, P. 107086 - 107086
Published: Jan. 29, 2024
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable delivery, companion diagnostics. By integrating cutting-edge technologies with delivery systems, greater precision achieved at tissue cellular levels use stimuli-responsive nanoparticles, development electrochemical sensor systems. targeting – by virtue nanotechnology allows for therapy to directed specifically affected tissues while reducing side effects on healthy tissues. As such, nanomedicine has potential transform conditions such as cancer, genetic diseases, chronic illnesses facilitating precise delivery. Additionally, forms devices offer ability tailor unique needs each patient, thereby increasing therapeutic effectiveness compliance. Companion diagnostics further enable efficient monitoring response, enabling customized adjustments plan. question whether all approaches outlined here are viable alternatives current treatments is also discussed. In general, application field biomedicine may provide a strong alternative existing several reasons. this review, we aim present evidence that, although early stages, fully merging technology innovative shows promise successful across various areas, including cancer or diseases.
Language: Английский
Citations
72
Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 81, P. 104261 - 104261
Published: Feb. 13, 2023
Language: Английский
Citations
44
International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 275, P. 133526 - 133526
Published: July 2, 2024
Language: Английский
Citations
31
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 9, 2025
Abstract Influenza remains a persistent global health challenge, largely due to the virus’ continuous antigenic drift and occasional shift, which impede development of universal vaccine. To address this, identification broadly neutralizing antibodies their epitopes is crucial. Nanobodies, with unique characteristics binding capacity, offer promising avenue identify such epitopes. Here, we isolate purify hemagglutinin (HA)-specific nanobody that recognizes an H7 subtype influenza A virus. The nanobody, named E10, exhibits broad-spectrum binding, cross-group neutralization in vivo protection across various subtypes. Through phage display vitro characterization, demonstrate E10 specifically targets epitope on HA head part conserved lateral patch highly immunodominant upon infection. Importantly, immunization peptide including elicits cross-reactive mediates partial from lethal viral challenge. Our data highlights potential its associated as candidate for future prevention strategies.
Language: Английский
Citations
2
Molecules, Journal Year: 2023, Volume and Issue: 28(18), P. 6438 - 6438
Published: Sept. 5, 2023
Antibody engineering has developed into a wide-reaching field, impacting multitude of industries, most notably healthcare and diagnostics. The seminal work on developing the first monoclonal antibody four decades ago witnessed exponential growth in last 10–15 years, where regulators have approved antibodies as therapeutics for several diagnostic applications, including remarkable attention it garnered during pandemic. In recent become fastest-growing class biological drugs treatment wide range diseases, from cancer to autoimmune conditions. This review discusses field therapeutic stands today. It summarizes outlines clinical relevance application treating landscape diseases different disciplines medicine. nomenclature, various approaches therapies, evolution therapeutics. also risk profile adverse immune reactions associated with sheds light future applications perspectives drug discovery.
Language: Английский
Citations
29
ACS Nano, Journal Year: 2023, Volume and Issue: 17(5), P. 4315 - 4326
Published: Feb. 20, 2023
Uncontrolled inflammation is responsible for acute and chronic diseases in the lung. Regulating expression of pro-inflammatory genes pulmonary tissue using small interfering RNA (siRNA) a promising approach to combatting respiratory diseases. However, siRNA therapeutics are generally hindered at cellular level by endosomal entrapment delivered cargo organismal inefficient localization tissue. Here we report efficient anti-inflammatory activity vitro vivo polyplexes an engineered cationic polymer (PONI-Guan). PONI-Guan/siRNA efficiently deliver cytosol highly gene knockdown. Significantly, these exhibit inherent targeting inflamed lung following intravenous administration vivo. This strategy achieved effective (>70%) knockdown (>80%) silencing TNF-α lipopolysaccharide (LPS)-challenged mice low (0.28 mg/kg) dosage.
Language: Английский
Citations
27
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(8), P. 1059 - 1059
Published: Aug. 12, 2024
Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms enhancing drug effectiveness while mitigating side effects. Despite established success delivery oncology other disciplines, exploration inhaled therapies remains relatively nascent. NPs loaded with bronchodilators or anti-inflammatory agents exhibit promising potential for precise distribution throughout bronchial tree, offering targeted treatment respiratory diseases. This article conducts a comprehensive review applications medicine, highlighting their merits, ranging from heightened stability to exacting lung-specific delivery. It also explores cutting-edge technologies optimizing NP-loaded aerosol systems, complemented insights gleaned trials. Furthermore, examines current future prospects NP-based therapies. By synthesizing data perspectives, underscores transformative promise NP-mediated addressing chronic conditions such as obstructive pulmonary disease, pressing global health concern ranked third mortality rates. overview illuminates evolving landscape inhalation therapies, presenting optimistic avenues advancing medicine improving patient outcomes.
Language: Английский
Citations
12
Gene, Journal Year: 2024, Volume and Issue: 925, P. 148607 - 148607
Published: May 24, 2024
Language: Английский
Citations
9
mAbs, Journal Year: 2025, Volume and Issue: 17(1)
Published: April 9, 2025
Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance emergence new strains. In this context, novel therapeutic modalities essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for treatment several diseases, nanobodies derived from heavy chain-only have emerged promising "nanoscale warriors" against infections. Nanobodies possess unique structural properties that enhance their ability recognize diverse epitopes. Their small size also imparts properties, improved bioavailability, solubility, stability, proteolytic resistance, making them an ideal class therapeutics review, we discuss role antivirals various Techniques developing nanobodies, delivery strategies covered, challenges opportunities associated use therapies discussed. We offer insights into future nanobody-based research support managing
Language: Английский
Citations
1